Pyxant is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients.
Under the deal, Pyxant will offer bioanalytical method development, sample analysis and formulation development for early clinical trials conducted at DCR’s clinical research units.
DCR vice president of early clinical research Chad Jaeger said Pyxant’s proven track record and overall commitment to high quality aligns well with the company’s strategic growth objectives for early clinical research.
"This collaboration represents another step forward in providing comprehensive services aimed at accelerating drug development," Jaeger said.
Pyxant Labs president and CEO Maurice Gaubatz said the company is happy to further extend its collaboration with the team at DCR.
"DCR has built the best clinical research site that I have toured in the last 10 years," Gaubatz said.
"Their operations team at the site, corporate culture and high ethical approach made a compelling case for our association.
"Pairing DCR’s clinical execution with Pyxant’s bioanalytical services is a winning combination, exactly in line with our respective core competencies."